Sagimet Biosciences Inc. Files 2023 Annual Report on Form 10-K

Ticker: SGMT · Form: 10-K · Filed: Mar 25, 2024 · CIK: 1400118

Sentiment: neutral

Topics: 10-K, Sagimet Biosciences, Annual Report, Pharmaceutical, Financials

TL;DR

<b>Sagimet Biosciences Inc. has filed its 2023 10-K annual report detailing its financial performance and business operations.</b>

AI Summary

Sagimet Biosciences Inc. (SGMT) filed a Annual Report (10-K) with the SEC on March 25, 2024. Sagimet Biosciences Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing includes financial data and business operations for the period. The company's principal executive offices are located at 155 Bovet Rd., Suite 303, San Mateo, CA 94402. Sagimet Biosciences was formerly known as 3-V Biosciences, Inc., with a name change on May 21, 2007. The company is classified under the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking Sagimet Biosciences Inc., this filing contains several important signals. This 10-K filing provides investors and stakeholders with a comprehensive overview of Sagimet Biosciences' financial health, operational status, and strategic direction for the fiscal year 2023. Understanding the details within this report is crucial for assessing the company's performance, risks, and future prospects in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Sagimet Biosciences Inc. shows moderate risk based on this filing. The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as detailed in its 10-K filing.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Sagimet Biosciences' current financial position and potential challenges.

Key Numbers

Key Players & Entities

FAQ

When did Sagimet Biosciences Inc. file this 10-K?

Sagimet Biosciences Inc. filed this Annual Report (10-K) with the SEC on March 25, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Sagimet Biosciences Inc. (SGMT).

Where can I read the original 10-K filing from Sagimet Biosciences Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Sagimet Biosciences Inc..

What are the key takeaways from Sagimet Biosciences Inc.'s 10-K?

Sagimet Biosciences Inc. filed this 10-K on March 25, 2024. Key takeaways: Sagimet Biosciences Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing includes financial data and business operations for the period.. The company's principal executive offices are located at 155 Bovet Rd., Suite 303, San Mateo, CA 94402..

Is Sagimet Biosciences Inc. a risky investment based on this filing?

Based on this 10-K, Sagimet Biosciences Inc. presents a moderate-risk profile. The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as detailed in its 10-K filing.

What should investors do after reading Sagimet Biosciences Inc.'s 10-K?

Review the detailed financial statements and risk factors in the 10-K to understand Sagimet Biosciences' current financial position and potential challenges. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,378 words · 18 min read · ~15 pages · Grade level 16.4 · Accepted 2024-03-25 06:37:26

Key Financial Figures

Filing Documents

Business

Business 5 ITEM 1A.

Risk Factors

Risk Factors 59 ITEM 1B. Unresolved Staff Comments 108 ITEM 1C. Cybersecurity 108 ITEM 2.

Properties

Properties 108 ITEM 3.

Legal Proceedings

Legal Proceedings 108 ITEM 4. Mine Safety Disclosures 108 PART II ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 109 ITEM 6. Reserved 109 ITEM 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 110 ITEM 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 119 ITEM 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 120 ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 143 ITEM 9A.

Controls and Procedures

Controls and Procedures 143 ITEM 9B. Other Information 143 ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 143 PART III ITEM 10. Directors, Executive Officers and Corporate Governance 144 ITEM 11.

Executive Compensation

Executive Compensation 144 ITEM 12.

Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters 144 ITEM 13. Certain Relationships and Related Party Transactions, and Director Independence 144 ITEM 14. Principal Accountant Fees and Services 144 PART IV ITEM 15. Exhibits 145 ITEM 16. Form 10-K Summary 145

Signatures

Signatures 150 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) . All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: our financial performance; our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the scope, progress, results and costs of developing denifanstat or any other drug candidate

Business

Item 1. Business. Overview We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Denifanstat has been studied in over 740 people to date in our clinical trials, including our FASCINATE-1 and -2 clinical trials, and we are currently designing a pivotal Phase 3 program for denifanstat in MASH, which we plan to initiate in the second half of 2024 following our expected End-of-Phase 2 meeting with the FDA in the first half of 2024. In January 2024, we announced positive topline results at week 52 from our FASCINATE-2 Phase 2b clinical trial. The FASCINATE-2 Phase 2b clinical trial achieved statistically significant results on primary and multiple secondary endpoints at week 52 in 168 MASH patients, including statistically significant improvements in MASH resolution without worsening of fibrosis with 2-point reduction in NAFLD Activity Score (NAS) (denifanstat 36% vs. placebo 13%, p=0.0022), and 2-point reduction in NAS without worsening of fibrosis (denifanstat 52% vs. placebo 20%, p=0.0001). Denifanstat-treated patients also showed statistically significant fibrosis improvement by 1 stage with no worsening of MASH (denifanstat 41% vs. placebo 18%, p=0.0051), and also showed statistical significance in fibrosis improvement by an independent approach of artificial intelligence (AI) digital pathology-based qFibrosis assessment. Analyses of liver fat showed a greater proportion of MRI-derived proton density fat fraction (MRI-PDFF) 30% responders relative to placebo (denifanstat 65% vs. placebo 21%, p<0.0001). MRI-PDFF responders are patients w

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing